The immunoregulatory effects of CMV-infection in human fibroblasts and the impact on cellular senescence

Juliane Wolf, Birgit Weinberger and Beatrix Grubeck-Loebenstein*

Abstract

Background: As a chronic antigenic stressor human Cytomegalovirus (CMV) contributes substantially to age-related alterations of the immune system. Even though monocytes have the greatest propensity for CMV-infection and seem to be an important host for the virus during latency, fibroblasts are also discussed to be target cells of CMV in vivo. However, little is known so far about general immunoregulatory properties of CMV in fibroblasts. We therefore investigated the immunoregulatory effects of CMV-infection in human lung fibroblasts and the impact on replicative senescence.

Findings: We observed that CMV-infection led to the induction of several immunoregulatory host cell genes associated with the innate and adaptive immune system. These were genes of different function such as genes regulating apoptosis, cytokines/chemokines and genes that are responsible for the detection of pathogens. Some of the genes upregulated following CMV-infection are also upregulated during cellular senescence, indicating that CMV causes an immunological phenotype in fibroblasts, which is partially reminiscent of replicative senescent cells.

Conclusion: In summary our results demonstrate that CMV not only affects the T cell pool but also induces inflammatory processes in human fibroblasts.

Keywords: Cytomegalovirus, Aging, Fibroblasts, Replicative senescence

Introduction

Cytomegalovirus (CMV) is a ubiquitous beta-herpesvirus with a worldwide prevalence of 60-100% in the adult population [1]. Infection occurs early and leads to life-long persistence in the host. CMV is one of the most immuno-dominant antigens and stimulates immune responses of unprecedented magnitude [2]. Several studies have shown that latent infection with cytomegalovirus contributes to age-related alterations of the immune system, particularly of the T cell compartment as it drives the differentiation of T cells and accelerates immunosenescence [3]. In the human host CMV exhibits tropism among others for monocytes/macrophages, fibroblasts and endothelial cells [4-6]. Previous reports demonstrate that CMV induces premature senescence in early passage human fibroblasts. Similar to senescent cells, which have reached the limit of their replicative capacity [7], CMV-infected fibroblasts show intense senescence-associated β-Galactosidase (SA-β-gal) activity and increased mRNA expression of the cell cycle arrest gene p16 [8,9]. Replicatively senescent fibroblasts characteristically also produce increased levels of inflammatory molecules [10]. They may thus contribute to the development of subclinical age-related inflammatory processes (‘inflamm-aging’) [11] and are believed to support the development of age-related diseases [12]. It is an interesting and to our knowledge not yet addressed question, whether CMV-infection of human fibroblasts not only triggers replicative senescence, but also induces the inflammatory phenotype characteristic for this differentiation stage. This may be a trigger for a dysbalance between pro- and antiinflammatory mechanisms and accelerate immunosenescence from early life onwards. Therefore the aim of this study was to investigate the effect of CMV on the expression of genes associated with innate and adaptive immune response in human fibroblasts and to analyze...
if the expression of these genes causes an inflammatory state which is equal to that of replicative senescent cells.

Results and discussion

Previous work with fibroblasts showed that cellular senescence is associated with changes in gene expression, particularly of the cellular secretome (senescence-associated secretory phenotype; SASP) [10,13,14]. In our study a broad analysis of the mRNA expression of immunity-related genes in human lung fibroblasts of different passages of cultivation was carried out using the RT² Profiler PCR Array. We observed that 28 genes out of 84 investigated genes were differentially expressed in early versus late passage fibroblasts (see Table 1) supporting previous results of senescence-associated changes in gene expression. These are genes of different functional groups, with mainly genes for the detection of pathogens (e.g. TLR4), cytokines (e.g. IL6) or the innate immune response (e.g. PGLYRP3) being upregulated.

Previous studies showed that CMV induces premature senescence of infected cells [8,9]. In order to elucidate whether CMV also influences the immunological phenotype, the expression of a panel of genes in CMV-infected fibroblasts using a RT² Profiler PCR Array was analyzed. We could show that in vitro CMV-infection of early passage fibroblasts leads to the induction of 35 inflammatory genes. 9 of these genes ( = 25.7%, see Figure 1) upregulated following CMV-infection are genes that are also upregulated during replicative senescence of human fibroblasts (Table 1 depicted in bold), indicating that CMV causes an immunological phenotype in early passage fibroblasts which is to some extent equal to that of uninfected replicative senescent cells. The probability that this simultaneous regulation of genes associated in senescence and CMV-infection was just chance was below 10% and could have been even lower if more genes and not only immunoregulatory ones had been investigated. Most similarities were found in the regulation of genes coding for cytokines, chemokines and their receptors with the upregulation of IL6 being the most prominent example. In addition to the nine senescence-related genes CMV-infection triggered the upregulation of additional 26 immunoregulatory genes in early passage fibroblasts (see Table 1). These were mainly genes regulating apoptosis and the NFκB pathway. The expression of all 84 investigated genes was measured at four different time points (6, 24, 48 and 72 hours) after CMV-infection. Kinetics of gene regulation were variable for the individual genes and revealed three patterns of gene expression as shown in Figure 2. In most cases genes were maximally upregulated 24 hours post infection and either returned to basal level after 48 hours (Figure 2A) or showed a relatively stable activation (Figure 2B). Only few genes showed a continuous upregulation with a maximum at 72 hours post infection (Figure 2C) and none of the regulated genes was maximally upregulated 6 or 48 hours post infection. The maximally observed fold regulation of the genes following CMV-infection is shown in Table 1. Superarray data were validated and confirmed using qRT-PCR for several exemplary genes (data not shown).

In summary these data show that CMV influences the mRNA expression of immunity-related host cell genes and thereby causes a modification of the cellular microenvironment. Furthermore we demonstrate that beyond partially imitating senescence-related inflammation CMV induces a robust inflammatory response in fibroblasts, which may contribute to age-related inflammation later in life. We cannot exclude that infection with other viruses might induce similar responses. However, CMV has particularly been linked with cellular senescence [8,9,15]. In this context IL6 is of particular interest since previous studies showed that high IL6 expression in combination with CMV-infection is associated with an increased risk of frailty in elderly people [16]. In general, virus-induced alterations in the cellular expression of cytokines such as IL6 may be important for the activation of specific leukocytes and their recruitment to the site of infection, thereby playing a role in viral pathogenesis. However, inappropriate production of immunostimulatory molecules leads to the excessive activation of the immune system and thereby to chronic inflammation. Since CMV causes life-long chronic latency in different human cells, leading to chronic antigenic stimulation and to increased production of immunity-related genes, CMV contributes to inflammation and aggravates immunosenescence.

In order to demonstrate that the induction of immunity-related genes following CMV-infection is also translated on the protein level ELISA experiments were performed. IL6 cytokine secretion was chosen as an example and was measured in the supernatants of untreated and CMV-infected fibroblasts over a culture period of five days. As shown in Figure 3 mock-infected fibroblasts produced low levels of IL6, which accumulate in the supernatant over time. Upon CMV-infection high IL6 concentrations could be observed starting at day 3 confirming the gene regulation observed on transcriptional level.

In conclusion our results demonstrate that CMV not only affects the T cell pool but also induces inflammatory processes in human fibroblasts. Therefore early life infection with CMV and episodes of reactivation throughout life might induce immunoregulatory changes supporting inflammatory processes and disease later in life.

Materials and methods

Cells

Human diploid fetal lung fibroblasts (Mrc-5) were cultivated in DMEM (Gibco Invitrogen Corporation, Paisley, Scotland) supplemented with 10% FCS (Sigma-Aldrich, Vienna, Austria), 100 Units/mL penicillin, 100 µg/mL
Table 1 Differently expressed genes in early versus replicative senescent and CMV-infected versus untreated human lung fibroblasts

| Gene symbol | Gene name                              | Fold regulation in replicative senescent fibroblasts (mean ± S.E. M.) | Maximally observed fold regulation (mean ± S.E.M.) following CMV-infection |
|-------------|----------------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Apoptosis   |                                        |                                                                        |                                                                          |
| CASP1       | Caspase 1                              | -                                                                     | 2.4 ± 1.3                                                                |
| CASP4       | Caspase 4                              | -                                                                     | 2.3 ± 1.3                                                                |
| TGFB1       | Transforming growth factor, beta 1     | -                                                                     | 2.1 ± 0.9                                                                |
| TNFRSF1A    | Tumor necrosis factor receptor superfamily, member 1A | -                                                                     | 2.4 ± 1.6                                                                |
| Complement activation |                          |                                                                        |                                                                          |
| C5          | Complement component 5                 | -                                                                     | 2.3 ± 1.5                                                                |
| C8A         | Complement component 8, alpha polypeptide | 6.8 ± 0.8                                                             | -                                                                        |
| CD55        | CD55 molecule, accelerating factor for complement | -                                                                     | 4.3 ± 0.9                                                                |
| Cytokines, chemokines and their receptors |                              |                                                                        |                                                                          |
| CCL2        | Chemokine (C-C motif) ligand 2          | -                                                                     | 2.8 ± 1.8                                                                |
| CXCR4       | Chemokine receptor 4                   | -                                                                     | 57.8 ± 1.5                                                               |
| IFNA1       | Interferon, alpha 1                    | 3.7 ± 0.3                                                             | -                                                                        |
| IFNGR1      | Interferon gamma receptor 1            | 2.0 ± 0.4                                                             | 3.2 ± 1.6                                                                |
| IFNGR2      | Interferon gamma receptor 2            | -                                                                     | 2.2 ± 1.6                                                                |
| IL1A        | Interleukin 1, alpha                   | 64 ± 0.2                                                              | 64 ± 1.6                                                                |
| IL1B        | Interleukin 1, beta                    | 41 ± 0.1                                                              | 8.9 ± 1.7                                                               |
| IL1F5       | Interleukin 1 family, member 5         | 3.2 ± 1.2                                                             | -                                                                        |
| IL1F7       | Interleukin 1 family, member 7         | 8.9 ± 0.8                                                             | -                                                                        |
| IL6         | Interleukin 6 (interferon, beta 2)     | 10.2 ± 0.04                                                           | 8.3 ± 1.5                                                               |
| TNF         | Tumor necrosis factor                  | 3.2 ± 0.4                                                             | -                                                                        |
| Detection of pathogens |                              |                                                                        |                                                                          |
| TLR2        | Toll-like receptor 2                   | -                                                                     | 61 ± 5.4                                                                |
| TLR3        | Toll-like receptor 3                   | -                                                                     | 59 ± 3.9                                                                |
| TLR4        | Toll-like receptor 4                   | 3.8 ± 0.9                                                             | 5.4 ± 4.7                                                               |
| TLR6        | Toll-like receptor 6                   | 3.0 ± 0.2                                                             | -                                                                        |
| TOLLIP      | Toll interacting protein               | -                                                                     | 25 ± 1.3                                                                |
| Defense response |                          |                                                                        |                                                                          |
| CAMP        | Cathelicidin antimicrobial peptide     | 8.3 ± 0.6                                                             | -                                                                        |
| FN1         | Fibronectin 1                          | 2.5 ± 0.2                                                             | -                                                                        |
| IL1 receptor pathway |                      |                                                                        |                                                                          |
| IL1R1       | Interleukin 1 receptor, type 1         | -                                                                     | 2.9 ± 1.2                                                                |
| IL1R2       | Interleukin 1 receptor-like 2          | -                                                                     | 5.3 ± 2.5                                                                |
| IL1RAP      | Interleukin 1 receptor accessory protein | -                                                                     | 2.4 ± 1.8                                                                |
| IKKB        | Inhibitor of kappa light polypeptide gene enhancer | 2.8 ± 0.2                                                           | -                                                                        |
| MAPK8       | Mitogen activated protein kinase 8     | -                                                                     | 2.5 ± 1.5                                                                |
| MAPK14      | Mitogen activated protein kinase 14    | -                                                                     | 2.5 ± 1.3                                                                |
| Inflammatory response |                          |                                                                        |                                                                          |
| ADORA2A     | Adenosine A2a receptor                 | 12.2 ± 3.0                                                            | 4.2 ± 4.2                                                                |
| CCR3        | Chemokine (C-C motif) receptor 3       | 123 ± 0.8                                                             | -                                                                        |
| CD14        | CD14 molecule                          | 291 ± 1.0                                                             | -                                                                        |
| CYBB        | Cytochrome b-245, beta polypeptide     | 8.5 ± 0.5                                                             | -                                                                        |
| IRAK1       | Interleukin-1 receptor-associated kinase 1 | -                     | 3.2 ± 1.7                                                                |
| IRAK2       | Interleukin-1 receptor-associated kinase 2 | 2.4 ± 0.04             | 2.7 ± 1.5                                                                |
streptomycin (Invitrogen, Lofer, Austria) and 2 mM L-glutamine (Sigma-Aldrich) at 37°C and 5% CO₂. For the experiments early passage fibroblasts (#22 - #26), showing an exponential growth behavior, and late passage fibroblasts (#45 - #48), that had entered the state of terminally growth arrest, were used. To evaluate the state of senescence of the fibroblasts, activity of SA-β-galactosidase at pH 5.8 [17] and gene expression of p15, p16 and p21 were measured. For gene expression analysis early and late passage fibroblasts were used, whereas CMV-infection was performed with early passage fibroblasts.

Virus

Human cytomegalovirus (strain Town-eGFP) was propagated in MRC-5 cells. Infectious virus particles in the virus stock were quantified by a standard plaque assay. Briefly, 500 µL of varying virus dilutions were added to confluent MRC-5 cells in a 12-well plate. After two hours of incubation (37°C, 5% CO₂) virus suspension was removed, cell monolayers were covered with 2 mL DMEM containing 1% methylcellulose (Sigma-Aldrich) and incubated for 10 days. Then plaques were counted.

Table 1 Differently expressed genes in early versus replicative senescent and CMV-infected versus untreated human lung fibroblasts (Continued)

| Innate immune response | NOS2A Nitric oxide synthase 2A (inducible) | 4.7 ± 0.9 | - |
|-------------------------|--------------------------------------------|-----------|---|
|                         | PTA FR Platelet-activating factor receptor  | 4.5 ± 1.4 | - |
| DMBT1 Deleted in malignant brain tumors 1 | 8.9 ± 1.4 | - |
| PGLYRP1 Pseudoglycan recognition protein 1 | 10.7 ± 1.8 | - |
| PGLYRP3 Pseudoglycan recognition protein 3 | 12.0 ± 1.1 | - |
| SFTPD Surfactant, pulmonary-associated protein D | 10.0 ± 1.1 | - |
| NFκB pathway | CHUK Conserved helix-loop-helix ubiquitous kinase | - | 2.1 ± 1.3 |
| MyD88 Myeloid differentiation primary response gene | - | 3.9 ± 1.8 |
| NFKB2 Nuclear factor of kappa light polypeptide gene enhancer in B cells 2 (p49/p100) | - | 3.2 ± 1.6 |
| NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha | - | 2.0 ± 0.9 |
| TRAF6 TNF receptor-associated factor 6 | - | 2.3 ± 1.5 |
| Other group | COLEC12 Collectin subfamily member 12 | 2.2 ± 0.2 | - |
| HMOX1 Heme oxygenase 1 | - | 2.0 ± 0.0 |
| IRF1 Interferon regulatory factor 1 | - | 3.4 ± 1.8 |
| LY96 Lymphocyte antigen 96 | - | 2.6 ± 1.7 |
| NLRC4 NLR family, CARD domain containing 4 | 2.3 ± 0.2 | 2.7 ± 1.6 |
| TREM1 Triggering receptor expressed on myeloid cells 1 | 4.1 ± 1.1 | 10.0 ± 2.8 |

The fold regulation data represent the mean ± S.E.M. of three independent experiments calculated for each examined group and time point.

Figure 1 BioVenn diagram showing the number of immunity-related genes upregulated in replicative senescent and CMV-infected fibroblasts. Shown is the number of genes differentially expressed in late passage compared to early passage fibroblasts (senescence) and the number of genes differentially expressed in CMV-infected versus untreated fibroblasts (CMV). 9 genes are regulated in both analyses. Depicted are genes that were reproducibly regulated in three independent experiments.
under a fluorescence microscope. The viral concentration is expressed as plaque-forming units per mL (pfu/mL). All in vitro experiments with the virus were performed with a multiplicity of infection (MOI) of 1.

CMV-infection of fibroblasts

For CMV-infection fibroblasts were seeded in 6-well plates and maintained in supplemented DMEM until they reached 100% confluency. Culture medium was removed and replaced by virus-containing medium. Untreated fibroblasts were used as a control (mock-infected). Supernatants were collected over several days as indicated and used for cytokine profiling by ELISA. Additionally, cells were harvested for isolation of total mRNA.

Total RNA-isolation and qRT-PCR

Total cellular RNA was extracted from fibroblasts using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). 0.25-0.5 μg of total RNA was used for cDNA synthesis, which was performed using the Reverse Transcription system A3500 with Oligo (dT)-primers (Promega, Madison, USA). cDNA sequences were amplified by qRT-PCR using the ‘Light Cycler® 480 System’ with the 2 × LightCycler 480 SYBR Green 480 master mix (Roche, Basel, Switzerland). Sequence-specific oligonucleotide primers were designed using Primer3 software [18] and synthesized by MWG Biotech (Ebersberg, Germany).
RT² Profiler PCR Array
To determine the profile of genes associated with the human innate and adaptive immune response (for a complete list refer to http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-052A.html) of untreated and CMV-infected fibroblasts, a RT² Profiler PCR Array (SA Biosciences™/Qiagen) was used. The obtained data were analyzed using a Web-Based Data Analysis tool (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php).

Cytokine profiling
Supernatants of fibroblasts were analyzed in duplicates for the presence of IL6 protein by a commercially available ELISA kit (MabTech, Hamburg, Germany).

Acknowledgements
This work has been supported by the Austrian Science Funds (project P23308-B05) and a part of this project was supported by and carried out within the EU funded Network of Excellence: Lifespan (project EUPO134). We thank Michael Nevels and Christina Paulus from the University of Regensburg, Institute for Medical Microbiology and Hygiene, who provided us the human cytomegalovirus (strain Town-eGFP). Furthermore we thank Michael Keller and Brigitte Jenewein for outstanding technical support.

Authors’ contributions
JW carried out the in vitro experiments with the virus, performed the superarray, ELISA and the qRT-PCR, analyzed the data and prepared the manuscript. BW prepared the CMV stock and participated in the design of the study, analysis of the data and preparation of the manuscript. BGL designed the study and supervised the preparation of the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 19 January 2012 Accepted: 29 March 2012

References
1. Crough T, Khanna R: Immunobiology of human cytomegalovirus: from bench to bedside. Curr Microbiol 2009, 59:76-83.

2. Landolfo S, Gariglio M, Ghibaudo G, Lembo D: The human cytomegalovirus. Pharmacol Ther 2003, 98:269-297.

3. Arnold CR, Wolf J, Brunner S, Herndler-Brandstetter D, Grubeck-Loebenstein B: Gain and loss of T cell subsets in old age-age-related reshaping of the T cell repertoire. J Clin Immunol 2011, 31:137-146.

4. Ibanez CE, Schierer K, Ghazal P, Wiley C, Nelson JA: Human cytomegalovirus productively infects primary differentiated macrophages. J Virol 1991, 65:6581-6588.

5. Myerson D, Hackman RC, Nelson JA, Ward DC, McDougal JK: Widespread presence of histologically occult cytomegalovirus. Hum Pathol 1984, 15:430-439.

6. Sinzger C, Kahii M, Laib K, Klingen K, Rieger P, Plachter B, Jahn G: Tropism of human cytomegalovirus for endothelial cells is determined by a post-entry step dependent on efficient translocation to the nucleus. J Gen Virol 2000, 81:3021-3035.

7. Serrano M, Lin AW, McClurach ME, Beach D, Lowe SW: Oncogenic ras provokes premature cell senescence associated with accumulation of p33 and p16INK4a. Cell 1997, 88:593-602.

8. Noris E, Zannetti C, Demurtas A, Sinclair J, De Andrea M, Gariglio M, Landolfo S: Cell cycle arrest by human cytomegalovirus B6-kDa IE2 protein resembles premature senescence. J Virol 2002, 76:12135-12148.

9. Zannetti C, Mondoni M, De Andrea M, Capossi P, Hara E, Peters G, Ghibaudo G, Gariglio M, Landolfo S: The expression of p16INK4a tumor suppressor is upregulated by human cytomegalovirus infection and required for optimal viral replication. Virology 2006, 349:79-86.

10. Shilton DN, Chang E, Whitfield PS, Choi D, Funk WD: Microarray analysis of replicative senescence. Curr Biol 1999, 9:339-345.

11. Franceschi C, Bonafe M, Valensin S, Olivier F, De Luca M, Ottaviani E, de Benedictis G: Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000, 908:244-254.

12. Guanta B, Fernandez F, Nikolic WW, Obregon D, Raso E, Town T, Tan J: Inflamming as a prodrome to Alzheimer’s disease. J Neuroinflammation 2008, 5:1.

13. Campisi J: The role of cellular senescence in skin aging. J Invest Dermatol Symp Proc 1998, 3:1-5.

14. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J: Senescence-associated secretory phenotypes reveal cell non-autonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008, 6:2853-2868.

15. Brunner S, Herndler-Brandstetter D, Weinberger B, Grubeck-Loebenstein B: Persistent viral infections and immune aging. Ageing Res Rev 2011, 10:362-369.

16. Schmalz HM, Fied L, Xue QL, Walston J, Leng SX, Semba RD: Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women. J Am Geriatr Soc 2005, 53:747-754.

17. van der Laa B, Fenton MJ, Fusalimsky JD: Cytotoxic chemical detection of a senescence-associated beta-galactosidase in endothelial and smooth muscle cells from human and rabbit blood vessels. Exp Cell Res 1998, 241:309-315.

18. Rozen S, Skaltsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000, 132:365-386.

Cite this article as: Wolf et al.: The immunoregulatory effects of CMV-infection in human fibroblasts and the impact on cellular senescence. Immunity & Ageing 2012, 9:1.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit